Redefining the standard of care for low-grade serous ovarian cancer

Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated follo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical advances in hematology & oncology 2024-06, Vol.22 (5), p.205
Main Authors: Manning-Geist, Beryl L, Cantor, Tal, O'Cearbhaill, Róisín E, Grisham, Rachel N
Format: Article
Language:English
Subjects:
Carcinoma, Ovarian Epithelial - pathology
Carcinoma, Ovarian Epithelial - therapy
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - therapy
Female
Humans
Molecular Targeted Therapy
Neoplasm Grading
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Standard of Care
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors. Ongoing research efforts seek to leverage the unique features of low-grade serous carcinoma to refine treatment options for patients with this rare tumor subtype.
ISSN:1543-0790